After decades of research and development in RNA interference (RNAi), considered one of the most exciting discoveries in biology, the year 2018 saw the first-ever RNAi drug pass regulatory muster in the United States. Let's take a look at some of the biotechnology companies developing RNA-based therapeutics.
from RTT - Biotech http://bit.ly/2R2Daes
via IFTTT
No comments:
Post a Comment